CereSpir
engages in the research and development of therapeutics for alzheimer's disease... Read moreCereSpir
engages in the research and development of therapeutics for alzheimer's disease... Read more
News
Apr 16, 2020
GlobeNewswire
Press Release: CereSpir : CERESPIR INCORPORATED Identifies Possible Link Between COVID-19 Induced Brain Inflammation and Acute Respiratory Stress Syndrome Via Breakdown of the Blood-Brain Barrier
Apr 16, 2020
firstwordpharma
CereSpir: CERESPIR INCORPORATED Identifies Possible Link Between COVID-19 Induced Brain Inflammation and Acute Respiratory Stress Syndrome Via Breakdown of the Blood-Brain Barrier
Mar 26, 2019
FIRSTWORD PHARMA
CereSpir: CERESPIR INCORPORATED Assembles World Class Clinical Advisory Board Chaired by Professor Robert A. Hauser to Support CERESPIR's Parkinson's Disease Development Program for Itanapraced
Dec 10, 2018
The Korea Bizwire
CereSpir: CereSpir Incorporated and the National Neuroscience Institute Singapore Announce Positive Data Showing Beneficial Effects of CereSpir's Clinical Stage Compound Itanapraced in a LRRK2 Model of Parkinson's Disease
Dec 10, 2018
streetinsider
Press Release: CereSpir : CERESPIR INCORPORATED and the NATIONAL NEUROSCIENCE INSTITUTE SINGAPORE Announce Positive Data Showing Beneficial Effects of CERESPIR's Clinical Stage Compound Itanapraced in a LRRK2 Model of Parkin
Aug 29, 2016
SEC
CereSpir: Received $500K in Equity Funding
Apr 20, 2016
Business Wire
Press Release: CereSpir : Batten Disease Pipeline Review, H1 2016 - Research and Markets
Aug 19, 2015
BUSINESS WIRE
Press Release: CereSpir : Research and Markets: Batten Disease Pipeline Review, H2 2015 - Reviews Key Pipeline Products Under Drug Profile Section Which Includes, Product Description, MoA and R&D Brief, Licensing and Collaboration Details
Jul 14, 2015
GLOBENEWSWIRE
Press Release: CereSpir : CereSpir Incorporated Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease
Jul 01, 2015
BIOSPACE
CereSpir: Cerespir Submits Special Protocol Assessment Request To FDA For A Phase III Clinical Trial To Test The Ability Of CSP-1103 To Slow The Progression Of Mild Cognitive Impairment Due To Alzheimer's Disease
CereSpir Competitors
1
2
3
4
5
6
7
8
9
10